TopleyN.Animal models in peritoneal dialysis: more questions than answers?Perit Dial Int2005; 25: 33–4.
2.
IshiiY., SawadaT., ShimizuA., TojimbaraT., NakajimaI., FuchinoueS.An experimental sclerosing encapsulating peritonitis model in mice.Nephrol Dial Transplant2001; 16: 1262–6.
3.
SawadaT., IshiiY., TojimbaraT., NakajimaI., FuchinoueS., TeraokaS.The ACE inhibitor, quinapril, ameliorates peritoneal fibrosis in an encapsulating peritoneal sclerosis model in mice.Pharmacol Res2002; 46: 505–10.
4.
SugaH., TeraokaS., OtaK., KomemushiS., FurutaniS., YamauchiS.Preventive effect of pirfenidone against experimental sclerosing peritonitis in rats.Exp Toxicol Pathol1995; 47: 287–91.
5.
LiuL., ShiC.X., GhayurA., ZhangC., SuJ.Y., HoffC.M.Prolonged peritoneal gene expression using a helper-dependent adenovirus.Perit Dial Int2009; 29: 508–16.
6.
HiguchiC., TanihataY., NishimuraH., NaitoT., SanakaT.Effects of glucose and plasminogen activator inhibitor-1 on collagen metabolism in the peritoneum.Ther Apher Dial2005; 9: 173–81.
7.
RoY., HamadaC., InabaM., IoH., KanekoK., TominoY.Inhibitory effects of matrix metalloproteinase inhibitor ONO-4817 on morphological alterations in chlorhexidine gluconate-induced peritoneal sclerosis rats.Nephrol Dial Transplant2007; 22: 2838–48.
8.
IoH., HamadaC., RoY., ItoY., HiraharaI., TominoY.Morphologic changes of peritoneum and expression of VEGF in encapsulated peritoneal sclerosis rat models.Kidney Int2004; 65: 1927–36.
9.
GarosiG., CappellettiF., Di PaoloN.Fibrosis and sclerosis: different disorders or different stages?Contrib Nephrol2006; 150: 62–9.
10.
KawanishiH.The pathogenesis and therapeutic option of encapsulating peritoneal sclerosis.Int J Artif Organs2005; 28: 150–5.
11.
YaoQ., PawlaczykK., AyalaE.R., StyszynskiA., BreborowiczA., HeimburgerO.The role of the TGF/Smad signaling pathway in peritoneal fibrosis induced by peritoneal dialysis solutions.Nephron Exp Nephrol2008; 109: e71–8.
12.
GraingerD.J., HeathcoteK., ChianoM., SniederH., KempP.R., MetcalfeJ.C.Genetic control of the circulating concentration of transforming growth factor type beta1.Hum Mol Genet1999; 8: 93–7.
13.
MancarellaL., Bobbio-PallaviciniF., CeccarelliF., FalapponeP.C., FerranteA., MalesciD.Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study.J Rheumatol2007; 34: 1670–3.
14.
SimoR., HernandezC.Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy.Diabetologia2008; 51: 1574–80.
